3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors, Adult
1
Skin Neoplasms
1
Lung Neoplasms
1
Lung Diseases
1
Colorectal Neoplasms
1
Carcinoma
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
Ipilimumab
29
Nivolumab
23
pembrolizumab
14
incomplete Freund's adjuvant
10
Cyclophosphamide
10
Interleukin-2
9
Melphalan
8
CTLA-4 Antigen
8
sargramostim
7
Temozolomide
7
MART-1 Antigen
7
Dacarbazine
7
tebentafusp
6
Ranibizumab
6
montanide ISA 51
5
fludarabine phosphate
5
fludarabine
5
Sunitinib
5
Radiosurgery
5
Carboplatin
5
Bevacizumab
5
aldesleukin
4
aflibercept
4
Magnetic Resonance Spectroscopy
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Blood Specimen Collection
4
Biopsy
4
trametinib
3
sotrastaurin
3
relatlimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Uveal Melanoma
×
Toll-Like Receptor 1
×
Clear all
NCT05576077
2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1
Terminated
31 enrolled